NCT05588297View on ClinicalTrials.gov

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

October 31, 2025

Conditions
Colorectal Cancer Liver Metastases
Interventions
DRUG

CapOx(Capecitabine+ Oxaliplatin)

CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles

DRUG

Bevacizumab

Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles

DRUG

Nivolumab

Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER

NCT05588297 - Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases | Biotech Hunter | Biotech Hunter